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Abstract: Background and objectives: To perform a updated systematic review and meta-analysis
comparing effectiveness of percutaneous nephrolithotomy (PCNL), retrograde intrarenal surgery
(RIRS), and extracorporeal shock wave lithotripsy (ESWL) for treatment of renal stones (RS). Materials
and Methods: A total of 37 studies were included in this systematic review and meta-analysis about
effectiveness to treat RS. Endpoints were stone-free rates (SFR), incidence of auxiliary procedure,
retreatment, and complications. We also conducted a sub-analysis of ≥2 cm stones. Results: First,
PCNL had the highest SFR than others regardless of stone sizes and RIRS showed a higher SFR than
ESWL in <2 cm stones. Second, auxiliary procedures were higher in ESWL than others, and it did not
differ between PCNL and RIRS. Finally, in <2 cm stones, the retreatment rate of ESWL was higher
than others. RIRS required significantly more retreatment procedures than PCNL in ≥2 cm stones.
Complication was higher in PCNL than others, but there was no statistically significant difference in
complications between RIRS and PCNL in ≥2 cm stones. For ≥2 cm stones, PCNL had the highest
SFR, and auxiliary procedures and retreatment rates were significantly lower than others. Conclusions:
We suggest that PCNL is a safe and effective treatment, especially for large RS.
Keywords: urolithiasis; percutaneous nephrolithotomy (PCNL); retrograde intrarenal surgery (RIRS);
extracorporeal shock wave lithotripsy (SWL)
1. Introduction
Urolithiasis, a major clinical and economic burden for healthcare systems [1], causes
severe pain in the flank or abdomen that may be accompanied by blood in the urine,
vomiting, or painful urination. In addition, urinary stones have a 1-year recurrence rate of
7% and 10-year recurrence rate of 50% [2]. Although urinary stones have been successfully
treated, these high recurrence rates make urolithiasis an important health issue requiring
additional treatments [3].
As minimally invasive technologies develop, percutaneous nephrolithotomy (PCNL),
retrograde intrarenal surgery (RIRS), and extracorporeal shock wave lithotripsy (ESWL)
are the most commonly performed treatments for kidney stones [4,5]. The European
Association of Urology (EAU) guidelines of urolithiasis suggests various treatments by
stone type and size [6]. Unlike the EAU guidelines, ESWL is currently used to treat most
cases since it can be performed easily without hospitalization [7]. However, ESWL often
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requires multiple treatments because of poor clearance and leads to surgical delays or an
increasing burden of expenses [8].
Some systematic reviews have compared renal stone treatments. Our study expands
on the existing systematic reviews by addressing the most comprehensive and updated
data. Some studies [9–11] compared just two kinds of treatments [9–11], while others [4,12]
compared all three but not by stone size [4,12]. Therefore, the present systematic review
and meta-analysis compares RIRS, PCNL, and ESWL for renal calculus by stone size and
analyzes treatment efficacy using various indexes like clinical aspects, retreatment rate,
and complications.
2. Materials and Methods
2.1. Inclusion Criteria
The selected studies were included based on the following set of inclusion criteria:
(a) patient with calculus of the kidney; (b) comparative interventions between ESWL,
PCNL, and RIRS to treat renal stones; and (c) reporting of at least one of the following
outcome measures: stone-free rates (SFRs), complications, retreatment procedure, and
auxiliary procedure. Search restrictions were set for English publication and human
species. This report was prepared in compliance with the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses statement (accessible at http://www.prisma-
statement.org/) [13]. The study was exempt from requiring approval of ethics committee
or institutional review board because of systematic review and meta-analysis.
2.2. Search Strategy
A systemic review was performed to identify relevant studies that compared inter-
ventions used to treat calculus of the kidney using three English databases Ovid-Medline
(1946–December 2017), Ovid-EMBASE (1974—December 2017), and the Cochrane Central
Register of controlled Trials (1945–December 2017). We designed strategies that included
Medical Subject Headings keywords such as “kidney calculi” “ureterolithiasis” “urolithiasis”
“shock wave lithotripsy” “SWL” “percutaneous nephrolithotomy” “PCNL” “retrograde
intrarenal surgery” “RIRS” “flexible ureteroscopy” “URSL” and combinations of search
terms. Table 1 shows the characteristics of the included studies (Supplement Table S1).
2.3. Study Selection and Data Extraction
To exclude irrelevant studies, two reviewers (SHL and CHK) independently screened
the titles and abstracts of the articles and subsequently performed full-text screens of
the potentially relevant articles. Two reviewers extracted the baseline demographics and
clinical characteristics (i.e., age, sex) of the study participants onto a data extraction form
and double-checked them.
2.4. Quality Assessment
A quality assessment was also independently performed by two reviewers (SHL
and CHK) using the criteria provided by Scottish Intercollegiate Guidelines Network
(SIGN). All discrepancies were resolved by discussion with a third reviewer. The SIGN
checklist was used to assess the quality of randomized and nonrandomized studies with
the advantage of a comprehensive parts assessment [14]. The tool consists of three areas:
internal validity, overall assessment, and description [15]. The overall quality of the articles
was indicated as 1++, 1+, and 1−.
2.5. Heterogeneity Tests
The heterogeneity of the included studies was examined using the Q statistic and
Higgins’ I2 statistic [16]. Higgins’ I2 measures the percentage of total variation due to
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in which “Q” is the Cochran’s heterogeneity statistic, and “df” is the degrees of freedom.
An I2 ≥ 50% is considered to represent substantial heterogeneity [17]. For the Q
statistic, heterogeneity was deemed to significant at values of p < 0.10 [18]. If there was
evidence of heterogeneity, the data were analyzed using a random-effects model. Studies
in which positive results had been confirmed were assessed with a pooled specificity using
95% confidence intervals (CIs) [19,20].
2.6. Statistical Analysis
For dichotomous variables, the risk ratios (RRs) and weighted mean differences
were calculated and reported with 95% CIs. As appropriate based on the degree of
study heterogeneity, a random-effects model was applied to calculate summary mea-
sures. Meta-analyses were conducted using the Mantel–Haenszel and inverse variance
methods, respectively. We conducted all meta-analyses using Review Manager version
5.3 (RevMan, Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration,
2013). All p-values were two-sided, and except for the test of discrepancy, a p < 0.05 was
considered statistically significant.
3. Results
After full-text review, 32 articles were identified as relevant for this study. Five
additional articles were included during our manual searches of the relevant bibliographies;
therefore, 37 publications were ultimately included in the meta-analysis (Figure 1).




Figure 1. Study flow chart. Thirty-seven studies were included in the qualitative analysis. 
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Table 1 shows the characteristics of the included studies. Twelve randomized con-
trolled clinical trials (RCTs) and 25 observational studies met the eligibility criteria. The 
selected studies were published between 1991 and 2017. Nineteen studies were conducted 
in the Middle East [3,21–38], six in Europe [39–44], four in Asia [45–48], four in North 
America [49–52], two in South America [53,54], and two in Africa [55,56]. A total of 1460 
PCNL cases, 1616 RIRS cases, and 2458 ESWL cases were compared in our meta-analysis. 
The included studies were divided by comparison type: Six compared PCNL and ESWL 
[25,44,49,51,54,55], 13 compared PCNL and RIRS [22,26,27,29–31,33,37–39,47,48,52], 13 
compared ESWL and RIRS [21,23,24,28,32,41–43,45,46,50,53,56], and five compared 
PCNL, ESWL, and RIRS [3,34–36,40]. Demographic characteristics such as mean age, sex 
ratio (male:female) were comparable among PCNL, RIRS, and ESWL study populations. 
(Table 1). 
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3.1. Characteristics of Included Studies
Table 1 shows the characteristics of the included studies. Twelve randomized con-
trolled clinical trials (RCTs) and 25 observational studies met the eligibility criteria. The
selected studies were published between 1991 and 2017. Nineteen studies were conducted
in the Middle East [3,21–38], six in Europe [39–44], four in Asia [45–48], four in North
America [49–52], two in South America [53,54], and two in Africa [55,56]. A total of
1460 PCNL cases, 1616 RIRS cases, and 2458 ESWL cases were compared in our meta-
analysis. The included studies were divided by comparison type: six compared PCNL and
ESWL [25,44,49,51,54,55], 13 compared PCNL and RIRS [22,26,27,29–31,33,37–39,47,48,52],
13 compared ESWL and RIRS [21,23,24,28,32,41–43,45,46,50,53,56], and five compared
PCNL, ESWL, and RIRS [3,34–36,40]. Demographic characteristics such as mean age, sex
ratio (male:female) were comparable among PCNL, RIRS, and ESWL study populations.
(Table 1).
3.2. Quality Assessment and Publication Bias
The results of the quality assessment based on the Scottish Intercollegiate Guidelines
Network checklist are shown in Table 1. Three studies [40,44,51] had a high risk of selection
bias, indicating a quality of 1-. Concealment method and blinding were not reported.
The funnel plot included in the meta-analysis is shown in Figure 2. There was little
publication bias in all analyses (Figure 2).
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Residual stone fragments







RCT + >2 cm
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patients with residual stone
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RCT + <1 cm, lower pole,asymptomatic
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≤3 cm, lower pole,
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Residual stone fragments




Hospital (Scotland) Prospective - 1–2 cm, lower pole
Residual stone








(Turkey) Retrospective ++ 2–4 cm
Radiological absence of
stone 146 146 - 46.33 ± 12.34 47.23 ± 15.16 104:42 98:48
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Retrospective + any size,symptomatic
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Residual stone























(Austria) Retrospective + ≤1.5 cm
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Residual stone















stone < 3 mm
140 46 251 36.4 ± 19.7 29.6 ± 20.3 30.8 ± 15.9 72:68 24:22 175:76
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Retrospective + 1–2 cm, lowerpole
Radiological absence
of stone, or residual
stone
fragments < 3 mm


































Retrospective + ≤2 cm, lowerpole
Radiological absence
of stone, or residual
stone
fragments < 3 mm




(US) Retrospective + 2–3 cm
Residual stone












Hospital (Brazil) Retrospective + ≤3 cm
Radiological absence
of stone 23 - 24 44 48 13:10 14:10
PCNL, percutaneous nephrolithotomy; RCT, randomized controlled trial; RIRS, retrograde intrarenal surgery; SWL, extracorporeal shock wave lithotripsy. * Age is shown as mean ± SD (standard deviation). The
overall quality of the articles was indicated as 1++, 1+, and 1− by Scottish Intercollegiate Guidelines Network (SIGN).
Medicina 2021, 57, 26 8 of 23Medicina 2021, 57, x FOR PEER REVIEW 11 of 26  
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bias in all studies. 
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3.3. Stone-Free Rate
Figure 3 shows a comparison of the SFRs of 37 studies. The definition between each
study of SFRs is described in Table 1. We defined 4 mm sized or less as clinically insignif-
icant residual fragments based on the definition of the included studies and previous
reference studies [57,58]. Therefore, regardless of the location of the renal stones, 4 mm
sized or less was defined as SFR and analyzed.
We conducted this meta-analysis according to intervention type and a sub-group
analysis of stone size. The analysis was performed according to comparison: PCNL and
ESWL, PCNL and RIRS, and ESWL and RIRS. PCNL provided a significantly higher SFR
than RIRS (p < 0.001; RR = 1.14; 95% CI, 1.06–1.22; I2 = 69%) and ESWL (p < 0.001; RR = 0.69;
95% CI, 0.61–0.78; I2 = 81%). RIRS provided a significantly higher SFR than ESWL (p < 0.001;
RR = 0.77; 95% CI, 0.67–0.88; I2 = 87%). A sub-group analysis was conducted based on the
criterion of 2-cm stone diameter. A comparison of SFRs is shown in Figure 4. In the group
of stones smaller than 2 cm, like in the primary analysis, PCNL provided a significantly
higher SFR than RIRS (p = 0.002; RR = 1.08; 95% CI, 1.02–1.14; I2 = 0%), and ESWL (p < 0.001;
RR = 0.76; 95% CI, 0.68–0.85; I2 = 63%). RIRS provided a significantly higher SFR than
ESWL (p < 0.001; RR = 0.82; 95% CI, 0.73–0.92; I2 = 79%). In the group of stones larger than
2 cm, like in the primary analysis, PCNL provided a significantly higher SFR than RIRS
(p < 0.001; RR = 1.23; 95% CI, 1.10–1.37; I2 = 74%), and ESWL (p < 0.001; RR = 0.72; 95% CI,
0.65–0.80), whereas no studies compared RIRS and ESWL.
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Figure 5. Meta-analysis of total complications: (a) ESWL vs. PCNL; (b) ESWL vs. RIRS; and (c) PCNL vs. RIRS. 
Sub-group analysis was conducted on the criterion of 2-cm stone diameter. A com-
parison of SFRs is shown in Figure 6. In the group of stones smaller than 2 cm, like in the 
primary analysis, ESWL resulted in fewer complications than PCNL (p < 0.001; RR = 0.29; 
95% CI, 0.16–0.52; I2 = 40%), whereas no statistically significant difference was found be-
tween ESWL and RIRS (p = 0.26; RR = 0.81; 95% CI, 0.56–1.17; I2 = 22%). RIRS resulted in 
fewer complications than PCNL (p = 0.009; RR = 2.05; 95% CI, 1.20–3.52; I2 = 0%). In the 
group of stones larger than 2 cm, unlike in the primary analysis, no significant difference 
was noted between PCNL and RIRS (p = 0.29; RR = 1.24; 95% CI, 0.84–1.83; I2 = 35%). No 
studies compared PCNL and ESWL or RIRS and ESWL. 
(A) (a) 
i re . eta-analysis of t tal c lic ti s: (a) ES vs. PC L; (b) ES L vs. RIRS; and (c) PC L vs. RIRS.
Sub-group analysis was conducted on the criterion of 2-cm stone diameter. A com-
parison of SFRs is sho n in Figure 6. In the group of stones s aller than 2 c , like in the
pri ary analysis, ES L resulted in fe er co licatio s t a ( 0.001; RR = 0.29;
95% CI, 0.16–0.52; I2 = 40%), whereas no statistically significant difference was found
between ESWL and IRS (p = 0.26; R = 0.81; 95% CI, 0.56–1.17; I2 = 22%). RIRS resulted in
fewer co plications than PCNL (p = 0.009; RR = 2.05; 95 CI, 1.20–3.52; I2 = 0 ). In the
group of stones larger than 2 c , unlike in the pri ary analysis, no significant difference
was noted between PCNL and RIRS (p = 0.29; RR = 1.24; 95% CI, 0.84–1.83; I2 = 35%).
No studies compared PCNL and ESWL or RIRS and ESWL.
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3.5. Retreatment Procedure 
A comparison of retreatment procedure is shown in Figure 7. Twenty-four studies 
reported on interventions as retreatment procedures. We conducted a meta-analysis ac-
cording to intervention type and a sub-group analysis of stone size. The analysis was per-
formed according to intervention type: PCNL versus SWL, PCNL versus RIRS, and SWL 
versus RIRS. ESWL required significantly more retreatment procedures than PCNL (p < 
0.001; RR = 11.92; 95% CI, 3.06–46.53; I2 = 87%), and RIRS (p = 0.001; RR = 5.75; 95% CI, 
1.99–16.60; I2 = 87%), while RIRS required significantly more retreatment procedures than 
PCNL (p = 0.02; RR = 0.29; 95% CI, 0.10–0.80; I2 = 66%). 
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3.5. Retreatment Procedure
A comparison of retreatment procedure is shown in Figure 7. Twenty-four studies
reported on interventions as retreatment procedures. We conducted a meta-analysis ac-
cording to intervention type and a sub-group analysis of stone size. The analysis was
performed according to intervention type: PCNL versus SWL, PCNL versus RIRS, and
SWL versus RIRS. ESWL required significantly more retreatment procedures than PCNL
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(p < 0.001; RR = 11.92; 95% CI, 3.06–46.53; I2 = 87%), and RIRS (p = 0.001; RR = 5.75; 95% CI,
1.99–16.60; I2 = 87%), while RIRS required significantly more retreatment procedures than
PCNL (p = 0.02; RR = 0.29; 95% CI, 0.10–0.80; I2 = 66%).









Figure 7. Meta-analysis of retreatment procedure: (a) ESWL vs. PCNL; (b) ESWL vs. RIRS; (c) PCNL vs. RIRS. 
A sub-group analysis was conducted of the criterion of 2-cm stone diameter. SFRs 
are compared in Figure 8. In the group of stones smaller than 2 cm, ESWL required sig-
nificantly more retreatment procedures than PCNL (p < 0.001; RR = 43.33; 95% CI, 7.45–
251.91; I2 = 39%), and RIRS (p = 0.001; RR = 6.25; 95% CI, 2.02–19.32; I2 = 89%), whereas 
there was no significant difference between PCNL and RIRS (p = 0.46; RR = 0.44; 95% CI, 
0.05–3.61; I2 = 0%). In the group of stones larger than 2 cm, like in the primary analysis, 
ESWL required significantly more retreatment procedures than PCNL (p < 0.001; RR = 
14.25; 95% CI, 7.50–27.07), and RIRS required significantly more retreatment procedures 
than PCNL (p = 0.01; RR = 0.22; 95% CI, 0.06–0.74, I2 = 75%). No studies compared RIRS 
and ESWL. 
Fig re 7. eta-analysis of retreat ent proce ure: (a) S vs. P ; ( ) S vs. I S; (c) P vs. I S.
analysis was conducted of the criterion of 2-cm stone diameter. SFRs are
compared in Figure 8. In the group of stones smaller th n 2 cm, ESWL required significantly
more retreatment procedures than PCNL (p < 0.001; RR = 43.33; 95% CI, 7.45–251.91;
I2 = 39%), and RIRS (p = 0.001; RR = 6.25; 95% CI, 2.02–19.32; I2 = 89%), whereas there w
no significant difference betw en PCNL a d RIRS (p = 0.46; RR 0.44; 95% CI, 0.0 –3.61;
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I2 = 0%). In the group of stones larger than 2 cm, like in the primary analysis, ESWL
required significantly more retreatment procedures than PCNL (p < 0.001; RR = 14.25;
95% CI, 7.50–27.07), and RIRS required significantly more retreatment procedures than
PCNL (p = 0.01; RR = 0.22; 95% CI, 0.06–0.74, I2 = 75%). No studies compared RIRS
and ESWL.













Figure 8. Meta-analysis (A). Retreatment procedure (stone size ≤ 2 cm): (a) ESWL vs. PCNL; (b) ESWL vs. RIRS; and (c) PCNL vs. 
RIRS. Meta-analysis (B). Retreatment procedure (stone size > 2 cm): (a) ESWL vs. PCNL; and (b) PCNL vs. RIRS. 
3.6. Auxiliary Procedure 
Figure 8. Meta-analysis (A). Retreatment procedure (stone size ≤ 2 cm): (a) ESWL vs. PCNL; (b) ESWL vs. RIRS; and (c)
PCNL vs. RIRS. Meta-analysis (B). Retreatment procedure (stone size > 2 cm): (a) ESWL vs. PCNL; and (b) PCNL vs. RIRS.
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3.6. Auxiliary Procedure
Auxiliary procedure is compared in Figure 9. Twenty studies were included for
auxiliary procedures. We conducted the meta-analysis of intervention types and then a sub-
group analysis of stone size. The analysis was performed of the compared interventions:
PCNL versus ESWL, PCNL versus RIRS, and ESWL versus RIRS. ESWL required more
auxiliary procedures than PCNL (p = 0.05; RR = 2.39; 95% CI, 1.01–5.61; I2 = 64%), whereas
there was no significant difference in use as an auxiliary procedure between ESWL and
RIRS (p = 0.41; RR = 1.29; 95% CI, 0.70–2.40; I2 = 53%) or between PCNL and RIRS (p = 0.74;
RR = 0.91; 95% CI, 0.50–1.63; I2 = 21%).
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the primary analysis, there was no significant difference in use as an auxiliary procedure
between ESWL and PCNL (p = F 0.75; RR = 1.45; 95% CI, 0.15–13.63; I2 = 81%), between
ESWL and RIRS (p = 0.56; RR = 1.2; 95% CI, 0.65–2.23; I2 = 54%), and between PCNL and
RIRS (p = 0.70; RR = 0.84; 95% CI, 0.34–2.07; I2 = 0%). In the group of stones larger than
2 cm, there was no significant difference in use as an auxiliary procedure between PCNL
and RIRS (p = 0.64; RR = 1.37; 95% CI, 0.37–5.03; I2 = 66%). Unlike in the primary analysis,
ESWL required a significantly more auxiliary procedure than PCNL (p < 0.001; RR = 5.34;
95% CI, 2.59–11.04). No study compared RIRS and ESWL.
We summarize all the analyzed results in Table 2. In addition, Table 2 also includes
sub-analysis on the lower pole stone.
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vs. RIRS. Meta-analysis B. Auxiliary procedure (stone size > 2 cm): (a) ESWL vs. PCNL; and (b) PCNL vs. RIRS. 
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Table 2. Summary of results.
Outcome No. of Studies RR (95% CI) p Value I2 (%)
ESWL vs. PCNL
Stone-free rate 11 0.69 (0.61–0.78) <0.00001 81
stone siz ≤ 2 cm 6 0.76 (0.68–0.85) <0.00001 63
stone size > 2 cm 1 0.72 (0.65–0.80) <0.00001 -
Lower pole stone 6 0.58 (0.44–0.76) 0.001 88
Total complication 6 0.28 (0.18–0.45) <0.00001 64
stone size ≤ 2 cm 4 0.29 (0.16–0.52) <0.0001 40
stone size > 2 cm 0 - - -
Lower pole stone 4 0.24 (0.14–0.41) <0.00001 57
Retreatment procedure 8 11.92 (3.06–46.53) 0.0004 87
stone size ≤ 2 cm 4 43.33 (7.45–251.91) <0.0001 39
stone size > 2 cm 1 14.25 (7.50–27.07) <0.00001 -
Lower pole stone 4 2.91 (0.99–8.56) 0.05 58
Auxiliary procedure 6 2.39 (1.01–5.61) 0.05 64
stone siz ≤ 2 cm 2 1.45 (0.15–13. 3) 0.75 81
stone size > 2 c 1 5.34 (2.59–11.04) <0.00001 -
Lower pole stone 3 1.56 (0.27–8.93) 0.62 70
Outcome No. of Studies RR (95% CI) p Value I2 (%)
ESWL vs. RIRS
Stone-free rate 18 0.77 (0.67–0.88) 0.0002 87
stone size ≤ 2 cm 15 0.82 (0.73–0.92) 0.0004 79
stone size > 2 cm - - - -
Lower pole stone 10 0.76 (0.60–0.97) 0.03 92
Total complication 12 0.87 (0.63–1.19) 0.38 16
stone size ≤ 2 cm 10 0.81 (0.56–1.17) 0.26 22
stone size > 2 cm - - - -
Lower pole stone 6 0.49 (0.29–0.83) 0.008 0
Retreatment procedure 10 5.75 (1.99–16.60) 0.001 87
stone s ze ≤ 2 cm 9 6.25 (2.02–19.32) 0.001 89
stone siz > 2 cm - - - -
Lower pole stone 3.96 (1.35–11.60) 0.01 63
Auxiliary procedure 10 1.29 (0.70–2.40) 0.41 53
stone size ≤ 2 cm 9 1.2 (0.65–2.23) 0.56 54
stone size > 2 cm - - -
Lower pole stone 5 1.46 (0.48–4.48) 0.50 70
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Table 2. Cont.
Outcome No. of studies RR (95% CI) p value I2 (%)
PCNL vs. RIRS
Stone-free rate 18 1.14 (1.06–1.22) 0.0003 69
stone size ≤ 2 cm 7 1.08 (1.02–1.14) 0.01 0
stone size > 2 cm 9 1.23 (1.10–1.37) 0.0003 74
Lower pole stone 5 1.34 (0.95–1.88) 0.10 89
Total complication 13 1.41 (1.06–1.86) 0.02 15
stone size ≤ 2 cm 5 2.05 (1.20–3.52) 0.009 0
stone size > 2 cm 6 1.24 (0.84–1.83) 0.29 35
Lower pole stone 4 1.99 (0.91–4.37) 0.09 10
Retreatment procedure 10 0.29 (0.10–0.80) 0.02 66
stone size ≤ 2 cm 2 0.44 (0.05–3.80) 0.46 0
stone size > 2 cm 7 0.22 (0.06–0.74) 0.01 75
Lower pole stone 2 0.20 (0.02–1.97) 0.17 20
Auxiliary procedure 9 0.91 (0.50–1.63) 0.74 21
stone size ≤ 2 cm 4 0.84 (0.34–2.07) 0.70 0
stone size > 2 cm 4 1.37 (0.37–5.03) 0.64 66
Lower pole stone 2 2.12 (0.36–12.47) 0.41 0
PNL, percutaneous nephrolithotomy; RIRS, retrograde intrarenal surgery; SWL, extracorporeal shock wave lithotripsy RR, risk ratio; CI,
confidence intervals.
4. Discussion
The use of minimally invasive techniques, such as PCNL, ESWL, and RIRS has in-
creased dramatically over the last 30 years through the sustained high incidence and
recurrence of renal stones [59]. New procedures are being introduced with the combination
of instruments and technology. Since Fernstrom and Johansson introduced PCNL for
the first time in 1976 as a surgical treatment for patients with large and complex renal
stones, PCNL has been considered a standard surgery for stones larger than 2 cm [60,61].
As advances in instruments and technology develop, PCNL has evolved from tubeless
PCNL to supine PCNL to mini PCNL [62–64]. Next, ESWL was first reported in 1984
after Chaussy and colleagues performed SWL on 852 patients [65]. SWL is a relatively
noninvasive procedure that has been used as a first treatment choice for small renal stones
less than 2 cm not within the lower pole of the kidney. Finally, RIRS has progressed rapidly
since the 1990 s, when the holmium:yttrium aluminum garnet laser system was introduced.
RIRS become popular with the development of the more durable models such as Flex-X
from Karl Storz Endoskope, Tuttlingen, Germany and URF-P from Olympus, Tokyo, Japan.
Also, the recently introduced compact aperture digital video scope and disposable video
scope contributed to becoming more popular of RIRS [66,67]. RIRS is constantly evolving
and has also recently been used to treat renal sinus cysts besides stones [68].
Three procedures are now widely used by urologists in the treatment of renal stones.
Guidelines recommend certain procedures according to stone location and size, but patient-
and doctor-related factors commonly result in other choices. The EAU guidelines [6]
suggest the use of ESWL or RIRS for the primary treatment of renal stones smaller than
2 cm and PCNL for the primary treatment of stones larger than 2 cm. Perhaps SFR is one of
the first points to consider when choosing among treatments for renal stones, as each has
its own advantages and disadvantages. Also, the complication and auxiliary procedure
rates may be important factors. Therefore, our meta-analysis aimed to help urologists make
better treatment decisions by providing them a comparison of these three procedures and
a sub-analysis by stone size (smaller versus greater than 2 cm).
In general, although PCNL is the most effective interventional therapy with the highest
SFR, careful patient selection is required due to its highly invasive nature [4,67]. In our
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results, PCNL also showed the best SFR for overall renal stone treatment, statistically
significantly compared to the other two procedures. In a sub-analysis according to stone
size, RIRS and PCNL showed a similar SFR for stones smaller than 2 cm, whereas PCNL
showed better results than RIRS for stones greater than 2 cm. As a result, PCNL had
the lowest retreatment rate. The complication rate, the largest disadvantage of PCNL,
was relatively higher than those of ESWL and RIRS when stone size was not considered.
However, complication rates did not differ between PCNL and RIRS in cases of stones
larger than 2 cm. This is the most important finding of our study since it demonstrates that
there is no need to choose ESWL or RIRS simply because of the high complication rate of
PCNL in renal stones greater than 2 cm. Recent reports have highlighted the advantage
of the decreased invasiveness of mini PCNL and ultra-mini PCNL [69,70]. We also think
that improvements to mini PCNL and ultra PCNL through the development of PCNL
technology have contributed greatly to reducing this complication rate.
There are several limitations to our study. First, sub-analysis according to location was
partially limited due to limitations in providing information according to stone location for
each study. Such an analysis may have led to different outcomes because the recommended
treatments vary depending on renal stone location. Next, sub-analyses of mini PCNL, ultra
PCNL, and conventional PCNL could not be performed. We think that further studies will
need to study the utility of PCNL types through these analyses. Finally, some degree of
publication bias was unavoidable, and the non-RCTs may involve additional selection bias.
Despite these limitations, our study still has its advantages. As mentioned earlier,
PCNL has already been presented as a first choice through the EAU guidelines in large renal
stones, but many urologists are concerned about PCNL-related complications. However,
our meta-analysis including all published studies showed that the complication rate of
PCNL is not high in cases of stones larger than 2 cm. Therefore, PCNL is a safe and effective
treatment, not a hazardous procedure, compared with other procedures for large renal
stones. We believe that this finding can guide the safety and efficacy of PCNL for urologists
treating large renal stones. This study may be a good source of information for patients
regarding renal stone therapy.
5. Conclusions
In our meta-analysis, among procedures for renal stones, PCNL had the highest SFR
and lower auxiliary procedure and retreatment rates than ESWL or RIRS. No statistically
significant difference was seen versus RIRS in complications regarding stones larger than
2 cm. Therefore, we suggest that PCNL is a safe and effective treatment, particularly for
large renal stones.
Supplementary Materials: The following are available online at https://www.mdpi.com/1010-660
X/57/1/26/s1, Table S1: Search terms and results.
Author Contributions: Conceptualization, C.H.K., D.Y.C. and S.H.L., J.Y.L.; methodology, C.H.K.,
D.Y.C.; validation, K.H.R., formal analysis, C.H.K., D.Y.C.; data curation, C.H.K., S.H.L.; writing—
original draft preparation, C.H.K., D.Y.C.; writing—review and editing, D.Y.C., S.H.L., J.Y.L.; visual-
ization, K.H.R., S.H.L. and J.Y.L.; supervision, S.H.L., J.Y.L.; project administration, S.H.L., J.Y.L. All
authors have read and agreed to the published version of the manuscript.
Funding: This study was supported by a grant from the Korea Health Technology R&D Project of the
Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare,
Republic of Korea (grant number: HC17C0005).
Institutional Review Board Statement: The study was exempt from requiring approval of ethics
committee or institutional review board because of systematic review and meta-analysis.
Informed Consent Statement: Patient consent was waived because this paper is systematic review
and meta-analysis.
Data Availability Statement: The data presented in this study are available in the article.
Conflicts of Interest: The authors report no conflicts of interest in relation to this work.
Medicina 2021, 57, 26 21 of 23
References
1. Romero, V.; Akpinar, H.; Assimos, D.G. Kidney stones: A global picture of prevalence, incidence, and associated risk factors. Rev.
Urol. 2010, 12, e86–e96.
2. Hesse, A.; Brandle, E.; Wilbert, D.; Kohrmann, K.U.; Alken, P. Study on the prevalence and incidence of urolithiasis in Germany
comparing the years 1979 vs. 2000. Eur. Urol. 2003, 44, 709–713. [CrossRef]
3. Bas, O.; Bakirtas, H.; Sener, N.C.; Ozturk, U.; Tuygun, C.; Goktug, H.N.; Imamoglu, M.A. Comparison of shock wave lithotripsy,
flexible ureterorenoscopy and percutaneous nephrolithotripsy on moderate size renal pelvis stones. Urolithiasis 2014, 42, 115–120.
[CrossRef]
4. Zhang, W.; Zhou, T.; Wu, T.; Gao, X.; Peng, Y.; Xu, C.; Chen, Q.; Song, R.; Sun, Y. Retrograde Intrarenal Surgery Versus Percutaneous
Nephrolithotomy Versus Extracorporeal Shockwave Lithotripsy for Treatment of Lower Pole Renal Stones: A Meta-Analysis and
Systematic Review. J. Endourol. 2015, 29, 745–759. [CrossRef]
5. Jung, H.D.; Kim, J.C.; Ahn, H.K.; Kwon, J.H.; Han, K.; Han, W.K.; Kim, M.D.; Lee, J.Y. Real-time simultaneous endoscopic
combined intrarenal surgery with intermediate-supine position: Washout mechanism and transport technique. Investig. Clin.
Urol. 2018, 59, 348–354. [CrossRef]
6. Turk, C.; Petrik, A.; Sarica, K.; Seitz, C.; Skolarikos, A.; Straub, M.; Knoll, T. EAU Guidelines on Interventional Treatment for
Urolithiasis. Eur. Urol. 2016, 69, 475–482. [CrossRef]
7. Chang, K.D.; Lee, J.Y.; Park, S.Y.; Kang, D.H.; Lee, H.H.; Cho, K.S. Impact of Pretreatment Hydronephrosis on the Success Rate of
Shock Wave Lithotripsy in Patients with Ureteral Stone. Yonsei Med. J. 2017, 58, 1000–1005. [CrossRef]
8. Kang, D.H.; Cho, K.S.; Ham, W.S.; Chung, D.Y.; Kwon, J.K.; Choi, Y.D.; Lee, J.Y. Ureteral stenting can be a negative predictor
for successful outcome following shock wave lithotripsy in patients with ureteral stones. Investig. Clin. Urol. 2016, 57, 408–416.
[CrossRef]
9. Zhu, W.; Liu, Y.; Liu, L.; Lei, M.; Yuan, J.; Wan, S.P.; Zeng, G. Minimally invasive versus standard percutaneous nephrolithotomy:
A meta-analysis. Urolithiasis 2015, 43, 563–570. [CrossRef]
10. Zheng, C.; Yang, H.; Luo, J.; Xiong, B.; Wang, H.; Jiang, Q. Extracorporeal shock wave lithotripsy versus retrograde intrarenal
surgery for treatment for renal stones 1–2 cm: A meta-analysis. Urolithiasis 2015, 43, 549–556. [CrossRef]
11. Zheng, C.; Xiong, B.; Wang, H.; Luo, J.; Zhang, C.; Wei, W.; Wang, Y. Retrograde intrarenal surgery versus percutaneous
nephrolithotomy for treatment of renal stones >2 cm: A meta-analysis. Urol. Int. 2014, 93, 417–424. [CrossRef] [PubMed]
12. Donaldson, J.F.; Lardas, M.; Scrimgeour, D.; Stewart, F.; MacLennan, S.; Lam, T.B.; McClinton, S. Systematic review and meta-
analysis of the clinical effectiveness of shock wave lithotripsy, retrograde intrarenal surgery, and percutaneous nephrolithotomy
for lower-pole renal stones. Eur. Urol. 2015, 67, 612–616. [CrossRef] [PubMed]
13. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA
statement. PLoS Med. 2009, 6, e1000097. [CrossRef] [PubMed]
14. Kim, K.; Kim, J.H.; Lim, K.-C.; Lee, K.-S.; Jeong, J.-S.; Choe, M.; Chae, Y.R. Quality assessment tools and reporting standards in
nursing research. J. Korean Biol. Nurs. Sci. 2012, 14, 221–230. [CrossRef]
15. Lim, S.M.; Shin, E.S.; Lee, S.H.; Seo, K.H.; Jung, Y.M.; Jang, J.E. Tools for assessing quality and risk of bias by levels of evidence. J.
Korean Med. Assoc. Taehan Uisa Hyophoe Chi 2011, 54, 419–429. [CrossRef]
16. Higgins, J.P.; Thompson, S.G.; Deeks, J.J.; Altman, D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327, 557–560.
[CrossRef]
17. Lee, J.Y.; Kang, D.H.; Chung, D.Y.; Kwon, J.K.; Lee, H.; Cho, N.H.; Choi, Y.D.; Hong, S.J.; Cho, K.S. Meta-Analysis of the
Relationship between CXCR4 Expression and Metastasis in Prostate Cancer. World J. Men’s Health 2014, 32, 167–175. [CrossRef]
18. Fleiss, J.L. Analysis of data from multiclinic trials. Control Clin. Trials 1986, 7, 267–275. [CrossRef]
19. L’Abbe, K.A.; Detsky, A.S.; O’Rourke, K. Meta-analysis in clinical research. Ann. Intern. Med. 1987, 107, 224–233. [CrossRef]
20. Galbraith, R.F. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat. Med. 1988, 7, 889–894.
[CrossRef]
21. Javanmard, B.; Kashi, A.H.; Mazloomfard, M.M.; Ansari Jafari, A.; Arefanian, S. Retrograde Intrarenal Surgery Versus Shock
Wave Lithotripsy for Renal Stones Smaller Than 2 cm: A Randomized Clinical Trial. Urol. J. 2016, 13, 2823–2828. [PubMed]
22. Karakoyunlu, N.; Goktug, G.; Sener, N.C.; Zengin, K.; Nalbant, I.; Ozturk, U.; Ozok, U.; Imamoglu, A. A comparison of standard
PCNL and staged retrograde FURS in pelvis stones over 2 cm in diameter: A prospective randomized study. Urolithiasis 2015, 43,
283–287. [CrossRef] [PubMed]
23. Sener, N.C.; Bas, O.; Sener, E.; Zengin, K.; Ozturk, U.; Altunkol, A.; Evliyaoglu, Y. Asymptomatic lower pole small renal stones:
Shock wave lithotripsy, flexible ureteroscopy, or observation? A prospective randomized trial. Urology 2015, 85, 33–37. [CrossRef]
[PubMed]
24. Sener, N.C.; Imamoglu, M.A.; Bas, O.; Ozturk, U.; Goktug, H.N.; Tuygun, C.; Bakirtas, H. Prospective randomized trial comparing
shock wave lithotripsy and flexible ureterorenoscopy for lower pole stones smaller than 1 cm. Urolithiasis 2014, 42, 127–131.
[CrossRef]
25. Yuruk, E.; Binbay, M.; Sari, E.; Akman, T.; Altinyay, E.; Baykal, M.; Muslumanoglu, A.Y.; Tefekli, A. A prospective, randomized
trial of management for asymptomatic lower pole calculi. J. Urol. 2010, 183, 1424–1428. [CrossRef]
Medicina 2021, 57, 26 22 of 23
26. Ozayar, E.; Gulec, H.; Bayraktaroglu, M.; Tutal, Z.B.; Kurtay, A.; Babayigit, M.; Ozayar, A.; Horasanli, E. Comparison of Retrograde
Intrarenal Surgery and Percutaneous Nephrolithotomy: From the View of an Anesthesiologist. J. Endourol. 2016, 30, 184–188.
[CrossRef]
27. Atis, G.; Culpan, M.; Pelit, E.S.; Canakci, C.; Ulus, I.; Gunaydin, B.; Yildirim, A.; Caskurlu, T. Comparison of Percutaneous
Nephrolithotomy and Retrograde Intrarenal Surgery in Treating 20-40 mm Renal Stones. Urol. J. 2017, 14, 2995–2999.
28. Gokce, M.I.; Tokatli, Z.; Suer, E.; Hajiyev, P.; Akinci, A.; Esen, B. Comparison of shock wave lithotripsy (SWL) and retrograde
intrarenal surgery (RIRS) for treatment of stone disease in horseshoe kidney patients. Int. Braz. J. Urol. Off. J. Braz. Soc. Urol. 2016,
42, 96–100. [CrossRef]
29. Sari, S.; Ozok, H.U.; Cakici, M.C.; Ozdemir, H.; Bas, O.; Karakoyunlu, N.; Sagnak, L.; Senturk, A.B.; Ersoy, H. A Comparison of
Retrograde Intrarenal Surgery and Percutaneous Nephrolithotomy for Management of Renal Stones? 2 CM. Urol. J. 2017, 14,
2949–2954.
30. Bas, O.; Ozyuvali, E.; Aydogmus, Y.; Sener, N.C.; Dede, O.; Ozgun, S.; Hizli, F.; Senocak, C.; Bozkurt, O.F.; Basar, H.; et al.
Management of calyceal diverticular calculi: A comparison of percutaneous nephrolithotomy and flexible ureterorenoscopy.
Urolithiasis 2015, 43, 155–161. [CrossRef]
31. Koyuncu, H.; Yencilek, F.; Kalkan, M.; Bastug, Y.; Yencilek, E.; Ozdemir, A.T. Intrarenal Surgery vs. Percutaneous Nephrolithotomy
in the Management of Lower Pole Stones Greater than 2 cm. Int. Braz. J. Urol. Off. J. Braz. Soc. Urol. 2015, 41, 245–251. [CrossRef]
[PubMed]
32. Yuruk, E.; Binbay, M.; Ozgor, F.; Sekerel, L.; Berberoglu, Y.; Muslumanoglu, A.Y. Comparison of shockwave lithotripsy and flexible
ureteroscopy for the treatment of kidney stones in patients with a solitary kidney. J. Endourol. 2015, 29, 463–467. [CrossRef]
[PubMed]
33. Zengin, K.; Tanik, S.; Karakoyunlu, N.; Sener, N.C.; Albayrak, S.; Tuygun, C.; Bakirtas, H.; Imamoglu, M.A.; Gurdal, M. Retrograde
intrarenal surgery versus percutaneous lithotripsy to treat renal stones 2–3 cm in diameter. BioMed Res. Int. 2015, 2015, 914231.
[CrossRef] [PubMed]
34. Resorlu, B.; Unsal, A.; Ziypak, T.; Diri, A.; Atis, G.; Guven, S.; Sancaktutar, A.A.; Tepeler, A.; Bozkurt, O.F.; Oztuna, D. Comparison
of retrograde intrarenal surgery, shockwave lithotripsy, and percutaneous nephrolithotomy for treatment of medium-sized
radiolucent renal stones. World J. Urol. 2013, 31, 1581–1586. [CrossRef] [PubMed]
35. Ozturk, U.; Sener, N.C.; Goktug, H.N.; Nalbant, I.; Gucuk, A.; Imamoglu, M.A. Comparison of percutaneous nephrolithotomy,
shock wave lithotripsy, and retrograde intrarenal surgery for lower pole renal calculi 10–20 mm. Urol. Int. 2013, 91, 345–349.
[CrossRef] [PubMed]
36. Aboutaleb, H.; El-Shazly, M.; Badr Eldin, M. Lower pole midsize (1–2 cm) calyceal stones: Outcome analysis of 56 cases. Urol. Int.
2012, 89, 348–354. [CrossRef]
37. Akman, T.; Binbay, M.; Ozgor, F.; Ugurlu, M.; Tekinarslan, E.; Kezer, C.; Aslan, R.; Muslumanoglu, A.Y. Comparison of
percutaneous nephrolithotomy and retrograde flexible nephrolithotripsy for the management of 2–4 cm stones: A matched-pair
analysis. BJU Int. 2012, 109, 1384–1389. [CrossRef]
38. Bozkurt, O.F.; Resorlu, B.; Yildiz, Y.; Can, C.E.; Unsal, A. Retrograde intrarenal surgery versus percutaneous nephrolithotomy in
the management of lower-pole renal stones with a diameter of 15 to 20 mm. J. Endourol. 2011, 25, 1131–1135. [CrossRef]
39. Bryniarski, P.; Paradysz, A.; Zyczkowski, M.; Kupilas, A.; Nowakowski, K.; Bogacki, R. A randomized controlled study to analyze
the safety and efficacy of percutaneous nephrolithotripsy and retrograde intrarenal surgery in the management of renal stones
more than 2 cm in diameter. J. Endourol. 2012, 26, 52–57. [CrossRef]
40. Chan, L.H.; Good, D.W.; Laing, K.; Phipps, S.; Thomas, B.G.; Keanie, J.Y.; Tolley, D.A.; Cutress, M.L. Primary SWL Is an Efficient
and Cost-Effective Treatment for Lower Pole Renal Stones Between 10 and 20 mm in Size: A Large Single Center Study. J. Endourol.
2017, 31, 510–516. [CrossRef]
41. Burr, J.; Ishii, H.; Simmonds, N.; Somani, B.K. Is flexible ureterorenoscopy and laser lithotripsy the new gold standard for lower
pole renal stones when compared to shock wave lithotripsy: Comparative outcomes from a University hospital over similar time
period. Cent. Eur. J. Urol. 2015, 68, 183–186. [CrossRef] [PubMed]
42. Tauber, V.; Wohlmuth, M.; Hochmuth, A.; Schimetta, W.; Krause, F.S. Efficacy Management of Urolithiasis: Flexible Ureteroscopy
versus Extracorporeal Shockwave Lithotripsy. Urol. Int. 2015, 95, 324–328. [CrossRef]
43. Koo, V.; Young, M.; Thompson, T.; Duggan, B. Cost-effectiveness and efficiency of shockwave lithotripsy vs. flexible ureteroscopic
holmium:yttrium-aluminium-garnet laser lithotripsy in the treatment of lower pole renal calculi. BJU Int. 2011, 108, 1913–1916.
[CrossRef] [PubMed]
44. Havel, D.; Saussine, C.; Fath, C.; Lang, H.; Faure, F.; Jacqmin, D. Single stones of the lower pole of the kidney. Comparative results
of extracorporeal shock wave lithotripsy and percutaneous nephrolithotomy. Eur. Urol. 1998, 33, 396–400. [CrossRef] [PubMed]
45. Kumar, A.; Vasudeva, P.; Nanda, B.; Kumar, N.; Das, M.K.; Jha, S.K. A Prospective Randomized Comparison between Shock
Wave Lithotripsy and Flexible Ureterorenoscopy for Lower Caliceal Stones </=2 cm: A Single-Center Experience. J. Endourol.
2015, 29, 575–579. [CrossRef] [PubMed]
46. Singh, B.P.; Prakash, J.; Sankhwar, S.N.; Dhakad, U.; Sankhwar, P.L.; Goel, A.; Kumar, M. Retrograde intrarenal surgery vs.
extracorporeal shock wave lithotripsy for intermediate size inferior pole calculi: A prospective assessment of objective and
subjective outcomes. Urology 2014, 83, 1016–1022. [CrossRef]
Medicina 2021, 57, 26 23 of 23
47. Bai, Y.; Wang, X.; Yang, Y.; Han, P.; Wang, J. Percutaneous nephrolithotomy versus retrograde intrarenal surgery for the treatment
of kidney stones up to 2 cm in patients with solitary kidney: A single centre experience. BMC Urol. 2017, 17, 9. [CrossRef]
48. Jung, G.H.; Jung, J.H.; Ahn, T.S.; Lee, J.S.; Cho, S.Y.; Jeong, C.W.; Lee, S.B.; Kim, H.H.; Oh, S.J. Comparison of retrograde intrarenal
surgery versus a single-session percutaneous nephrolithotomy for lower-pole stones with a diameter of 15 to 30 mm: A propensity
score-matching study. Korean J. Urol. 2015, 56, 525–532. [CrossRef]
49. Preminger, G.M. Management of lower pole renal calculi: Shock wave lithotripsy versus percutaneous nephrolithotomy versus
flexible ureteroscopy. Urol. Res. 2006, 34, 108–111. [CrossRef]
50. Pearle, M.S.; Lingeman, J.E.; Leveillee, R.; Kuo, R.; Preminger, G.M.; Nadler, R.B.; Macaluso, J.; Monga, M.; Kumar, U.; Dushinski,
J.; et al. Prospective, randomized trial comparing shock wave lithotripsy and ureteroscopy for lower pole caliceal calculi 1 cm or
less. J. Urol. 2005, 173, 2005–2009. [CrossRef]
51. Albala, D.M.; Assimos, D.G.; Clayman, R.V.; Denstedt, J.D.; Grasso, M.; Gutierrez-Aceves, J.; Kahn, R.I.; Leveillee, R.J.; Lingeman,
J.E.; Macaluso, J.N., Jr.; et al. Lower pole I: A prospective randomized trial of extracorporeal shock wave lithotripsy and
percutaneous nephrostolithotomy for lower pole nephrolithiasis-initial results. J. Urol. 2001, 166, 2072–2080. [CrossRef]
52. Hyams, E.S.; Shah, O. Percutaneous nephrostolithotomy versus flexible ureteroscopy/holmium laser lithotripsy: Cost and
outcome analysis. J. Urol. 2009, 182, 1012–1017. [CrossRef] [PubMed]
53. Vilches, R.M.; Aliaga, A.; Reyes, D.; Sepulveda, F.; Mercado, A.; Moya, F.; Ledezma, R.; Hidalgo, J.P.; Olmedo, T.; Marchant, F.
Comparison between retrograde intrarenal surgery and extracorporeal shock wave lithotripsy in the treatment of lower pole
kidney stones up to 15 mm. Prospect. Randomized Study Actas Urol. Esp. 2015, 39, 236–242. [CrossRef]
54. Netto, N.R., Jr.; Claro, J.F.; Lemos, G.C.; Cortado, P.L. Renal calculi in lower pole calices: What is the best method of treatment? J.
Urol. 1991, 146, 721–723. [CrossRef]
55. Hassan, M.; El-Nahas, A.R.; Sheir, K.Z.; El-Tabey, N.A.; El-Assmy, A.M.; Elshal, A.M.; Shokeir, A.A. Percutaneous nephrolithotomy
vs. extracorporeal shockwave lithotripsy for treating a 20–30 mm single renal pelvic stone. Arab J. Urol. 2015, 13, 212–216.
[CrossRef] [PubMed]
56. El-Nahas, A.R.; Ibrahim, H.M.; Youssef, R.F.; Sheir, K.Z. Flexible ureterorenoscopy versus extracorporeal shock wave lithotripsy
for treatment of lower pole stones of 10–20 mm. BJU Int. 2012, 110, 898–902. [CrossRef]
57. Osman, Y.; Harraz, A.M.; El-Nahas, A.R.; Awad, B.; El-Tabey, N.; Shebel, H.; Shoma, A.M.; Eraky, I.; El-Kenawy, M. Clinically
insignificant residual fragments: An acceptable term in the computed tomography era? Urology 2013, 81, 723–726. [CrossRef]
58. Seitz, C.; Tanovic, E.; Kikic, Z.; Memarsadeghi, M.; Fajkovic, H. Rapid extracorporeal shock wave lithotripsy for proximal ureteral
calculi in colic versus noncolic patients. Eur. Urol. 2007, 52, 1223–1227. [CrossRef]
59. Kim, B.S. Recent advancement or less invasive treatment of percutaneous nephrolithotomy. Korean J. Urol. 2015, 56, 614–623.
[CrossRef]
60. Fernstrom, I.; Johansson, B. Percutaneous pyelolithotomy. A new extraction technique. Scand. J. Urol. Nephrol. 1976, 10, 257–259.
[CrossRef]
61. Wickham, J.E.; Miller, R.A.; Kellett, M.J.; Payne, S.R. Percutaneous nephrolithotomy: One stage or two? Br. J. Urol. 1984, 56,
582–585. [CrossRef] [PubMed]
62. Helal, M.; Black, T.; Lockhart, J.; Figueroa, T.E. The hickman peel-away sheath: Alternative for pediatric percutaneous nephrolitho-
tomy. J. Endourol. 1997, 11, 171–172. [CrossRef] [PubMed]
63. Rana, A.M.; Bhojwani, J.P.; Junejo, N.N.; Das Bhagia, S. Tubeless PCNL with patient in supine position: Procedure for all
seasons?—with comprehensive technique. Urology 2008, 71, 581–585. [CrossRef] [PubMed]
64. Zanetti, S.P.; Boeri, L.; Gallioli, A.; Talso, M.; Montanari, E. Minimally invasive PCNL-MIP. Arch Esp. Urol. 2017, 70, 226–234.
[PubMed]
65. Chaussy, C.; Schuller, J.; Schmiedt, E.; Brandl, H.; Jocham, D.; Liedl, B. Extracorporeal shock-wave lithotripsy (ESWL) for
treatment of urolithiasis. Urology 1984, 23, 59–66. [CrossRef]
66. Brandt, B.; Ostri, P.; Lange, P.; Kvist Kristensen, J. Painful caliceal calculi. The treatment of small nonobstructing caliceal calculi in
patients with symptoms. Scand. J. Urol. Nephrol. 1993, 27, 75–76. [CrossRef]
67. De, S.; Autorino, R.; Kim, F.J.; Zargar, H.; Laydner, H.; Balsamo, R.; Torricelli, F.C.; Di Palma, C.; Molina, W.R.; Monga, M.; et al.
Percutaneous nephrolithotomy versus retrograde intrarenal surgery: A systematic review and meta-analysis. Eur. Urol. 2015, 67,
125–137. [CrossRef]
68. Mancini, V.; Cormio, L.; d’Altilia, N.; Benedetto, G.; Ferrarese, P.; Balzarro, M.; Defidio, L.; Carrieri, G. Retrograde Intrarenal
Surgery for Symptomatic Renal Sinus Cysts: Long-Term Results and Literature Review. Urol. Int. 2018, 101, 150–155. [CrossRef]
69. Ferakis, N.; Stavropoulos, M. Mini percutaneous nephrolithotomy in the treatment of renal and upper ureteral stones: Lessons
learned from a review of the literature. Urol. Ann. 2015, 7, 141–148. [CrossRef]
70. Haghighi, R.; Zeraati, H.; Ghorban Zade, M. Ultra-mini-percutaneous nephrolithotomy (PCNL) versus standard PCNL: A
randomised clinical trial. Arab J. Urol. 2017, 15, 294–298. [CrossRef]
